Definium Therapeutics Income Statement (2019-2026) | DFTX

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Cost of Revenue (Quarter)
0.29M
Operating items
Amortization - Intangibles (Quarter)
3.26M3.26M
Research & Development (Quarter)
8.07M9.02M10.88M10.24M9.33M7.77M8.83M12.60M14.78M13.20M11.55M11.71M14.64M17.19M21.76M23.36M29.81M30.98M33.56M41.48M
Selling, General & Administrative (Quarter)
37.15M8.21M6.67M8.26M7.62M9.21M5.07M8.26M14.41M8.41M10.66M10.50M9.81M7.60M10.70M8.80M11.09M14.69M14.06M17.74M
Other Operating Expenses (Quarter)
-0.00M-0.04M
Operating Expenses (Quarter)
45.22M17.23M17.56M18.50M16.94M16.98M13.90M20.86M29.18M21.62M22.20M22.20M24.46M24.79M32.46M32.16M40.90M45.67M47.58M59.22M
Operating Income (Quarter)
-45.22M-17.23M56.52M-18.50M-16.94M-16.98M-13.90M-20.86M-29.18M-21.62M-22.20M-22.20M-24.46M-24.79M-32.46M-32.16M-40.90M-45.67M-47.58M-59.22M
EBIT (Quarter)
-45.22M-17.23M56.52M-18.50M-16.94M-16.98M-13.90M-20.86M-29.18M-21.62M-22.20M-22.20M-24.46M-24.79M-32.46M-32.16M-40.90M-45.67M-47.58M-59.22M
Non-operating items
Non Operating Investment Income (Quarter)
0.01M0.04M0.20M0.09M-0.26M
Interest & Investment Income (Quarter)
0.01M0.01M1.36M1.39M1.49M1.34M1.66M3.12M3.51M3.28M2.43M2.77M2.26M3.49M3.46M
Other Non Operating Income (Quarter)
-0.04M-0.04M-0.18M0.05M-0.01M0.14M0.10M-0.05M0.25M3.69M0.24M-32.20M18.60M11.11M5.03M-0.02M-0.05M-21.60M-0.13M-17.88M
Non Operating Income (Quarter)
-0.03M0.03M-0.43M0.05M-0.01M0.50M9.00M-3.95M0.05M3.69M-1.66M-32.20M18.60M11.11M-2.28M8.81M-1.84M-21.60M-2.86M-17.88M
Net income details
EBT (Quarter)
-45.25M-17.20M26.59M-18.50M-16.96M-16.48M56.86M-19.58M-27.87M-20.18M-21.51M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-56.96M
Tax Provisions (Quarter)
-1.16M
Profit After Tax (Quarter)
-45.25M-17.20M-16.83M-18.45M-16.96M-16.48M-4.90M-24.82M-29.13M-17.92M-23.86M-54.40M-5.85M-13.68M-34.74M-23.35M-42.74M-67.27M-50.44M-77.10M
Income from Continuing Operations (Quarter)
-45.25M-17.20M27.74M-18.50M-16.96M-16.48M56.86M-19.58M-27.87M-20.18M-21.51M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-56.96M
Consolidated Net Income (Quarter)
-45.25M-17.20M27.74M-18.50M-16.96M-16.48M56.86M-19.58M-27.87M-20.18M-21.51M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-56.96M
Income towards Parent Company (Quarter)
-45.25M-17.20M27.74M-18.50M-16.96M-16.48M56.86M-19.58M-27.87M-20.18M-21.51M-20.98M-21.81M-22.01M-29.84M-30.33M-40.47M-44.68M-45.37M-56.96M
Net Income towards Common Stockholders (Quarter)
-45.25M-17.20M27.74M-18.50M-16.96M-16.48M56.86M-19.58M-27.87M-20.18M-21.51M-54.40M-19.30M-22.04M-34.74M-30.35M-42.74M-67.27M-50.44M-77.10M
Additional items
EPS (Basic) (Quarter)
-0.11-0.61-0.59-0.66-0.60-0.56-0.02-0.65-0.76-0.45-0.59-1.14-0.08-0.18-0.42-0.27-0.50-0.78-0.50-0.71
EPS (Weighted Average and Diluted) (Quarter)
-0.11-0.61-0.59-0.66-0.60-0.56-0.02-0.65-0.76-0.45-0.59-1.14-0.26-0.27-0.42-0.35-0.50-0.78-0.50-0.71
Shares Outstanding (Weighted Average) (Quarter)
400.32M27.12M0.27M28.15M19.29M29.30M30.86M38.08M38.58M38.80M39.16M47.86M59.89M65.94M70.46M85.07M85.35M85.89M4.20M100.21M
Shares Outstanding (Diluted Average) (Quarter)
400.32M420.06M27.38M28.15M28.24M28.57M30.86M38.08M38.58M39.72M39.16M47.86M75.30M80.24M70.46M89.33M
EBITDA (Quarter)
-44.55M-17.58M-16.45M-18.50M-17.10M-16.59M-5.02M-24.80M-29.41M-17.51M-24.30M-53.91M-5.86M-13.70M-34.74M-23.36M-42.74M-67.07M-50.35M-77.36M
Interest Expenses (Quarter)
0.08M0.08M0.05M0.65M0.43M0.47M0.73M0.66M0.60M2.34M1.27M1.29M1.20M
Tax Rate (Quarter)
-4.35%